Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Abstract: The present invention relates to compositions, methods, uses and kits for combination therapies involving immunotherapies, such as adaptive cell therapy, e.g., T cell therapy, and an oncolytic virus (particularly parvovirus H-1), for treating subjects with cancer. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the cancer is a solid tumor or a hematological malignancy.

Abstract: The present invention relates to a method for color visualization and separation of a natural and medical image comprising pixels defined by color pixel vector a=[a1a2, a3] in a Cartesian color space (e.g. RGB), where the color pixel vector is represented by a pure quaternion q=+a1i+a2j+a3k with i,j, k satisfying: i2=j2=k2=ijk=?1, ij=?ji=k,jk=?kj=i, ki=?ik=j and the image is decomposed into q+ and q using the orthogonal 2D planes split concept according to: (formula (I)) wherein/and g are pure unit quaternions or f and g describe interactively determined or computed colors (s1, s2). The method allows not only visualizing and separating certain colors in a digital image in a rapid fashion, but also permits a flexible definition pertinent to the kind of colors that can be visualized or separated by defining the corresponding decompositions by means of pure unit quaternions/and g. Colors s1, s2 can be defined manually or computed automatically from the image.

Abstract: Described is an anti-HSV antibody or an antigen-binding fragment thereof for use in treating an acute infection of mucosal or epidermal tissue in a subject caused by HSV-1 or HSV-2 selected from the group consisting of Herpes simplex labialis, Herpes simplex genitalis, chronic or disseminated cutaneous herpes simplex infection, Herpes gladiatorum and Eczema herpeticum, wherein said antibody is to be topically administered as well as to a pharmaceutical composition comprising an effective amount of said antibody or antigen-binding fragment thereof and at least one pharmaceutically acceptable excipient.

Abstract: Described is an anti-HSV antibody or an antigen-binding fragment thereof for use in treating an acute infection of mucosal or epidermal tissue in a subject caused by HSV-1 or HSV-2 selected from the group consisting of Herpes simplex labialis, Herpes simplex genitalis, chronic or disseminated cutaneous herpes simplex infection, Herpes gladiatorum and Eczema herpeticum, wherein said antibody is to be topically administered as well as to a pharmaceutical composition comprising an effective amount of said antibody or antigen-binding fragment thereof and at least one pharmaceutically acceptable excipient.

Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Abstract: The present invention relates to a modified viral structural protein (VSP) as a tool for specifically targeting a chimeric antigen receptor (CAR) expressed on cells of the immune system. The modified VSPs can assemble into virus like particles (VLP). Exposed areas of the VSPs are modified to comprise in a region located atthe surface of a higher order structure, e.g. such as a capsomeric structure, a capsid, a VLP, a viral vector or a virus, a ligand specifically binding to a CAR (LCAR). The present invention thus, provides a modified VSP. The invention also relates to a nucleic acid encoding said VSP. Further, the invention relates to a capsomeric structure, a capsid, a VLP, a viral vector or a virus comprising at least one VSP. Further, the invention relates to a pharmaceutical composition comprising the VSP, the nucleic acid, the capsomeric structure, the capsid, the VLP, the viral vector or the virus comprising at least one VSP.

Abstract: The present invention relates to a method for color visualization and separation of a natural and medical image comprising pixels defined by color pixel vector a=[a1a2, a3] in a Cartesian color space (e.g. RGB), where the color pixel vector is represented by a pure quaternion q=+a1i+a2j+a3k with i,j, k satisfying: i2=i2=k2=ijk=?1, ij=?ji=k,jk=?kj=i, ki=?ik=j and the image is decomposed into q+ and q using the orthogonal 2D planes split concept according to: (formula (I)) wherein/and g are pure unit quaternions or f and g describe interactively determined or computed colors (s1, s2). The method allows not only visualizing and separating certain colors in a digital image in a rapid fashion, but also permits a flexible definition pertinent to the kind of colors that can be visualized or separated by defining the corresponding decompositions by means of pure unit quaternions/and g. Colors s1, s2 can be defined manually or computed automatically from the image.

Abstract: The present invention relates to CCRS antagonists for use in the treatment of cancer, either in monotherapy or in combination therapy. The invention also relates to methods for determining whether a subject suffering from cancer benefits from an ongoing therapeutic treatment with a CCRS antagonist or whether a subject suffering from cancer will benefit from a planned therapeutic treatment with a CCRS antagonist.

Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Abstract: The present invention relates to CCRS antagonists for use in the treatment of cancer, either in monotherapy or in combination therapy. The invention also relates to methods for determining whether a subject suffering from cancer benefits from an ongoing therapeutic treatment with a CCRS antagonist or whether a subject suffering from cancer will benefit from a planned therapeutic treatment with a CCRS antagonist.

Abstract: Described is an anti-HSV antibody or an antigen-binding fragment thereof for use in treating an acute infection of mucosal or epidermal tissue in a subject caused by HSV-1 or HSV-2 selected from the group consisting of Herpes simplex labialis, Herpes simplex genitalis, chronic or disseminated cutaneous herpes simplex infection, Herpes gladiatorum and Eczema herpeticum, wherein said antibody is to be topically administered as well as to a pharmaceutical composition comprising an effective amount of said antibody or antigen-binding fragment thereof and at least one pharmaceutically acceptable excipient.

Abstract: Provided are novel human tumor-specific antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigen NY-ESO-1. In addition, pharmaceutical compositions comprising such antibodies and mimics thereof in the treatment of tumors are described.

Abstract: The invention relates to the discovery of cancer antigens associated with ovarian cancer. In further aspects, the invention relates to methods, compositions and kits for the diagnosis and treatment of cancer, particularly ovarian and pancreatic cancers.

Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.

Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.

Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.

Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.

Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.